Summary: In 6068 patients with type 2 diabetes and a recent acute coronary event, adding lixisenatide to usual care was non-inferior to placebo for the composite of cardiovascular death, myocardial infarction, stroke or hospitalisation for unstable angina (13.4% vs 13.2%; hazard ratio 1.02; 95% CI 0.89 to 1.17) over a median of 25 months. Superiority was not shown (p=0.81).
PICO Summary
| Element | Detail |
|---|---|
| Population | 6068 patients with type 2 diabetes who had a myocardial infarction or were hospitalised for unstable angina within the previous 180 days; randomised, placebo-controlled trial; median follow-up 25 months. |
| Intervention | Lixisenatide added to locally determined standard of care. |
| Comparison | Placebo added to locally determined standard of care. |
| Outcome | Primary composite (cardiovascular death, myocardial infarction, stroke or hospitalisation for unstable angina): 406 (13.4%) vs 399 (13.2%); HR 1.02 (95% CI 0.89 to 1.17); p<0.001 for non-inferiority (upper confidence limit below 1.3), p=0.81 for superiority. Hospitalisation for heart failure: HR 0.96 (95% CI 0.75 to 1.23). Death: HR 0.94 (95% CI 0.78 to 1.13). No excess of serious adverse events, severe hypoglycaemia, pancreatitis, pancreatic neoplasms or allergic reactions. |
Expert Commentary
My verdict is neutral. ELIXA was designed as a safety trial and it answered the safety question cleanly. In 6068 patients with type 2 diabetes and an acute coronary event in the previous 180 days, major cardiovascular events occurred in 13.4% on lixisenatide and 13.2% on placebo over a median of 25 months (hazard ratio 1.02; 95% CI 0.89 to 1.17), which met the non-inferiority margin but showed no superiority (p=0.81). Heart failure hospitalisation (hazard ratio 0.96) and death (hazard ratio 0.94) did not differ, and there was no signal for pancreatitis, pancreatic neoplasms or severe hypoglycaemia. The limitation I weigh most is the population. These were patients in the early period after an acute coronary syndrome, followed for a median of 25 months, so the trial cannot be read as a verdict on the whole drug class, because the later outcome trials in this class gave different results. The trial was funded by the manufacturer. Can I use this with my patients? Lixisenatide can be regarded as cardiovascular-safe after a recent coronary event, but it should not be chosen for cardiovascular protection. I would prefer an agent with a positive outcome trial in that setting.
References
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247-57. doi:10.1056/NEJMoa1509225. PMID: 26630143.

